Last reviewed · How we verify

Veregen only — Competitive Intelligence Brief

Veregen only (Veregen only) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botanical extract / polyphenol immunomodulator. Area: Oncology / Dermatology.

marketed Botanical extract / polyphenol immunomodulator Oncology / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Veregen only (Veregen only) — University of Texas Southwestern Medical Center. Veregen is a polyphenon E extract that induces apoptosis and inhibits growth of human papillomavirus (HPV)-infected cells through multiple molecular pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Veregen only TARGET Veregen only University of Texas Southwestern Medical Center marketed Botanical extract / polyphenol immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botanical extract / polyphenol immunomodulator class)

  1. University of Texas Southwestern Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Veregen only — Competitive Intelligence Brief. https://druglandscape.com/ci/veregen-only. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: